Mesa Laboratories (MLI) AI Stock Analysis
Mesa Laboratories
(Frankfurt:MLI)
No summary available
Mesa Laboratories (MLI) vs. iShares MSCI Germany ETF (EWG)
- Market Cap
- EUR 715.21M
- Dividend Yield
- 0.47%
- Average Volume (3M)
- 323
- Price to Earnings (P/E)
- 148.6
- Beta (1Y)
- 0.88
- Revenue Growth
- -4.04%
- EPS Growth
- ―
- Country
- Germany
- Employees
- 717
- Sector
- Technology
- Sector Strength
- 61
- Industry
- Medical - Specialties
Mesa Laboratories Business Overview & Revenue Model
Company Description
Mesa Laboratories, Inc. develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control seg...
Mesa Laboratories Earnings Call Summary
The call balanced clear operational progress and improving financial metrics (modest revenue growth, margin expansion, AOI improvement, strong cash flow and debt reduction) with material execution challenges in SDC (quarterly revenue decline, delivery reliability and backlog volatility) and some non-operating volatility from currency impacts. Management presented a concrete remediation plan (operations focus, R&D reprioritization for Gyrolab, new commercial leadership in BPD) and committed to delivering full-year guidance in November, suggesting confidence in a fixable path forward.
Q1-2027 Updates
Positive Updates
Negative Updates
Company Guidance
Mesa deferred full‑year fiscal 2027 guidance to its November earnings call alongside first‑half results, saying Q1 trends are consistent with its internal plan and that the company returned to organic growth in Q1 (total revenues $60.1M, organic growth 1%, core organic ex‑currency 0.4%). Management will continue deleveraging — Q1 saw an $8.7M debt paydown that brought net leverage to 1.85x with a target range of 1.5–1.75x by year‑end — while maintaining liquidity ($30.7M cash) and strong operating cash flow ($14.7M in Q1, up $12.8M YoY). They plan to redeploy a portion of operating leverage into higher‑return businesses rather than pursue large M&A, noting trailing 12‑month adjusted operating income (ex‑unusual items) of ~ $66M (up ~$2.5M) and Q1 adjusted operating income of $15M (25.6% of revenues, $2.61/diluted share; $15.4M excluding a $382k legal settlement); full‑year revenue and market assumptions will be provided in November.
Mesa Laboratories Risk Analysis
Mesa Laboratories disclosed 47 risk factors in its most recent earnings report. Mesa Laboratories reported the most risks in the "Legal & Regulatory" category.
Latest Risks Added
0 New RisksMesa Laboratories Peers Comparison
Overall Rating
STE78Outperform
MASS60Neutral
LAB46Neutral
QDEL46Neutral
TRIB37Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| STE | 78Outperform | $22.14B | 27.70 | 11.27% | 1.14% | 8.37% | 23.94% |
| Sector * | 61Neutral | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% |
| MASS | 60Neutral | $465.00M | -12.10 | -25.50% | ― | 0.72% | 56.39% |
| LAB | 46Neutral | $240.77M | -2.65 | -18.16% | ― | -45.15% | 29.58% |
| QDEL | 46Neutral | $908.62M | -0.86 | -55.30% | ― | -2.57% | -135.75% |
| TRIB | 37Underperform | $4.04M | -0.14 | 48.72% | ― | -13.28% | 39.65% |
* Technology Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| DE:MLI | Mesa Laboratories | 118.00 | 56.91 | 93.17% | |
| LAB | Standard Biotools Inc | 0.61 | -0.63 | -50.81% | |
| QDEL | Quidelortho Corporation | 13.25 | -14.46 | -52.18% | |
| STE | Steris | 227.12 | -7.60 | -3.24% | |
| TRIB | Trinity Biotech | 6.26 | -23.16 | -78.72% | |
| MASS | 908 Devices Inc. | 11.25 | 3.32 | 41.87% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.